Business
BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth
BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing natural and engineered phage therapies designed to target and destroy harmful bacteria in chronic diseases, today announced the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer.
About this update from Biomx Inc.
[{"type":"text","content":"Seasoned financial leaders join BiomX to support strategic execution and advancement of the company","length":99,"tagName":"p","attribs":{}},{"type":"text","content":"DOVER, Del. and NESS ZIONA, Israel, March 9, 2026 /PRNewswire/ -- BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing natural and engineered phage therapies designed to target and destroy harmful bacteria in chronic diseases, today announced the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer.","length":364,"tagName":"p"},{"type":"text","content":"Oster brings extensive experience in corporate strategy, mergers and acquisitions, and operational leadership across capital-intensive industries including energy, infrastructure, and industrial sectors. Throughout his career, he has led complex transactions and built operational platforms designed to support long-term shareholder value. Currently, Oster serves as CEO and board member of Saffron Tech Ltd., an agritech company focused on innovative saffron cultivation technologies, as well as a member of the Board of Directors of BladeRanger Ltd., a publicly traded Israeli innovator in advanced drone payload systems for defense, homeland security, and solar applications.","length":678,"tagName":"p"},{"type":"text","content":"Earlier in his career, Oster served as Senior Vice President of Mergers and Acquisitions at Alon USA Energy, Inc., where he led numerous strategic transactions during the company's growth as a publicly traded energy company with approximately $8 billion in revenue.","length":269,"tagName":"p"},{"type":"text","content":"David Rokach joins the company as Chief Financial Officer. He brings more than two decades of experience in finance, investment management, and corporate leadership. Rokach will oversee BiomX's financial strategy, capital markets activities, accounting, and investor relations. Rokach serves as a member of the board of directors of T3 Defense Inc. since 2024. He previously served as Chief Executive Officer of Newcom Finance and Granit Investment Company, and has advised corporations and hedge funds on strategic and financial initiatives.","length":546,"tagName":"p"},{"type":"text","content":""The company is entering an important phase as we evaluate business opportunities and continue executing on our devel...